MSLN and mesothelioma: The AUC of serum mesothelin to distinguish patients with mesothelioma from those with benign asbestos pleurisy was not different from that of serum midkine (p = 0.1641) or that of the combination of the two biomarkers (p = 0.1055) (Fig. 2b).